Partnership with The Michael J. Fox Foundation
Given ND Biosciences’ commitment todeploy its expertise, technical capabilities and integrated platforms to accelerate the discovery and validation of novel targets and therapeutics for neurodegenerative diseases, ND Biosciences has embarked on a strategic partnership with The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to make available a limited set of its uniqueproteoforms to members of the scientific community.
This partnership follows ND Biosciences’ successful completion of a project that was supported by MJFF, through which ND Biosciences developed, characterized and validated protein standards that would enable accurate assessment of the levels ofα-Syn oligomers in biological samples.
Through this new distribution partnership, ND Biosciences’ will make available well-characterized preparations of α-Syn oligomers and α-Syn monomer controls, to non- and for-profit entities for their own R&D purposes. These unique protein tools provide a wide-range of discovery and translational research applications, including for structural biology research, protein-protein interactions, target validation studies, high-throughput assay screening, biomarker discovery, assay development and diagnostics.
For all proteins, ND Biosciences applies an integrated battery of orthogonal characterization
techniques to establish protein purity, integrity and conformational properties.
α-Syn oligomers will be in turn be characterized by coomassie staining, western blotting, CD spectroscopy, and transmission electron microscopy (TEM).
For α-Syn monomers, ND Biosciences will perform thorough characterization using mass spectrometry, ultra-performance liquid chromatography (UPLC), coomassie staining, endotoxin level determination, dynamic light scattering and circular dichroism (CD) spectroscopy.
Importantly, the full battery of techniques will be applied on each generated lot, and the corresponding characterization data of each lot will be provided to distributees for their own R&D purposes. This would allow research groups to compare and build-upon data obtained at different labs using the same lot of proteins, thereby improving the quality, reproducibility and integrity of research on neurodegenerative diseases. Our ultimate goal by making these unique tools available is to promote collaborations and synergies across the field, that will lead to better treatment options for patients suffering from NDs.
Pricing, ordering information, and sample datasheets are provided below:
| Tool | Conditioning (mg) | Non-profit distributee price (CHF) | For-profit distributee price (CHF) |
|---|---|---|---|
|
α-Syn monomers |
1 |
250 |
300 |
|
|
0.5 |
160 |
200 |
|
|
0.1 |
75 |
90 |
|
α-Syn oligomers |
0.5 |
3000 |
3750 |
|
|
0.25 |
1600 |
2000 |
|
|
0.1 |
700 |
900 |
Please submit your request to
proteintools@nd-biosciences.com
Distribution is planned starting November 15th 2021
Bulk orders and larger amounts of individual proteins are to be discussed with ND Biosciences. We also welcome discussions on collaborative projects and partnerships related to our protein engineering platforms and ability to reproduce the normal and pathologic proteoforms of other proteins linked to NDs (e.g., Amyloid-β, Tau, α-Syn, TDP-43 and huntingtin).